Letters and urgent communications 2022
Date published:
Last updated:
Advice from the Chief Medical Officer to HSC professionals for 2022
Documents
- HSS(MD) 60 2022 - Valproate - Drug safety update - Reminder of the current pregnancy prevention programme requirements; information on new safety measures to be introduced in the coming months
- HSS(MD)59/2022 - Middle east respiratory syndrome coronavirus (mers-cov)-risks associated with travel to Qatar FIFA world cup
- HSS MD 58 2022 Confirmed Influenza in Northern Ireland NICE Guidance on use of Antivirals now applies
- HSS(MD) 57 2022 - COVID-19 Therapeutic Alert - Interleukin-6 Inhibitors (Tocilizumab or Sarilumab) for Adult Patients Hospitalised due to COVID-19
- HSS(MD) 56 2022 - COVID-19 Therapeutic Alert - Treatment of Hospital-Onset COVID-19 in Adults and Children
- HSS(MD) 55 2022 Baricitinib for Patients Hospitalised due to COVID-19 (Adults and Children Aged 2 Years and Over)
- HSS(MD) 54 2022 - COVID-19 Therapeutic Alert - Remdesivir for Patients Hospitalised due to COVID-19– Update
- HSS(MD) 53 2022 COVID 19 Therapeutic Alert - Treatments for Highest Risk Non Hospitalised Patients (Adults and Children) With COVID 19
- Letter from Professor Sir Michael McBride - Winter Period 2022
- HSS(MD) 52 2022 - Guidance On Place Of Birth - Immediate Action Required
- HSS(MD) 51/2022 - Letter to all frontline health and social care workers - encouraging everyone to be vaccinated for influenza and Covid-19 this Autumn / Winter
- HSS(MD) 50/2022 - Updated Covid-19 testing guidance to support clinical pathways
- HSS MD 49 2022 - Public health message to all Health and Social Care providers regarding Ebola virus outbreak in Uganda (Sudan ebolavirus)
- HSS (MD) 48/2022 - Monkeypox Vaccination
- HSS (MD) 47/2022 - Update on advice for primary covid-19 vaccination of children turning 5 years of age
- Addendum HSS (MD) 46/2022 - Guidance on the revised arrangements for the certification and registration of deaths and stillbirths and the cremation process
- HSS (MD) 46/2022 - Guidance on the revised arrangements for the certification and registration of deaths and stillbirths and the cremation process
- Further Addendum to HSS (MD) 37/2022 - World Patient Safety Day - 17 September 2022 - Events Postponed
- HSS (MD) 45/2022 - Tecovirimat as a treatment for patients hospitalised due to Monkeypox viral infection
- HSS (MD) 44/2022 - Emergency Planning Policy, Governance And Reporting Changes
- Addendum to HSS (MD) 37/2022 - World Patient Safety Day - 17 September 2022
- HSS (MD) 43 - 2022 - European Medicines Agency (EMA) approval of Comirnaty and Spikevax bivalent Original - Omicron BA.1 Covid-19 vaccines
- HSS(MD) 42/2022 - Shingles vaccination programme – eligibility criteria for 2022/23
- HSS (MD) 41/2022 - Seasonal influenza vaccination programme 2022/23
- HSS(MD)40/2022 - Supply and packaging of QIV and LAIV vaccine during 2022/23 influenza season
- HSS (MD) 39/2022 - Covid-19 booster vaccination programme for autumn 2022
- HSS (MD) 38/2022 - Limited supplies of Varivax® and Varilrix® injection available until mid October 2022
- HSS(MD) 37/2022 - World patient safety day - 17 September 2022
- HSS(MD) 36/2022 - National Patient Safety Alert – Shortage of Alteplase and Tenecteplase Injections
- HSS(MD) 35/2022 - Monkeypox Vaccination
- HSS(MD) 34/2022 - Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure
- HSS(MD) 33 2022 - Palivizumab passive immunisation against respiratory syncytial virus (RSV) in at-risk pre-term infants – start of programme
- HSS(MD) 32/2022 - Monkeypox Vaccination
- HSS(MD) 31/2022 - Covid-19 spring booster vaccination programme
- HSS(MD) 30/2022 - Monkeypox becomes a notifiable disease in Northern Ireland
- HSS(MD) 29/2022 - Covid-19 therapeutic alert: antivirals or neutralising monoclonal antibodies (nMABs) for non-hospitalised patients with Covid-19
- HSS(MD) 28/2022 - Covid-19 therapeutic alert: antivirals and neutralising monoclonal antibodies (nMABs) in the treatment of hospital-onset Covid-19
- HSS(MD) 27/2022 - Legal advice on the withdrawal of life sustaining treatment for pregnant women who lack capacity to consent
- HSS(MD) 26/2022 - Responsibility for prescribing between Primary and Secondary and Tertiary Care Services for the supply of Medicines and other pharmaceutical products
- HSS(MD)25/2022 - Immediate Actions in Response to Cases of MonkeyPox Virus in UK with no Known Travel History
- HSS(MD) 24/2022 - Safety of Pregabalin (Lyrica) in Pregnancy: MHRA Drug Safety Update and Findings of Safety Study on Risks During Pregnancy
- HSS(MD)23/2022 - Labelling of Vaxzevria® (Astrazeneca) Covid-19 vaccine
- HSS (MD) 22/2022 - Updated Covid testing guidance to support clinical pathways
- HSS(MD) 21/2022 - Permanent suspension of the 15 minute with Covid-19 vaccines
- HSS(MD)20/2022 - Covid-19 treatments for non-hospitalised patients
- HSS(MD)19/2022 - Covid-19 Therapeutic Alert: Baricitinib for Patients Hospitalised due to Covid-19 (Adults and Children aged 2 years and over)
- HSS(MD) 18 2022 - New Statutory Rules - The General Medical Services Contracts (Amendment) Regulations (NI) 2022 and The Pharmaceutical Services (Amendment) Regulations (NI) April 2022
- HSS(MD) 17/2022 - Updated Covid testing and isolation guidance for health and social care workers and guidance on visitor testing
- HSS(MD) 16/2022 - End of the 2021/22 flu season and related issues
- HSS (MD) 15/2022 - Transition of the operational control of the Covid-19 vaccination programme to the PHA
- HSS(MD) 14/2022 Transfer of the Controlled Drugs Accountable Officer role to the Department of Health following the closure of the Health and Social Care Board
- HSS (MD) 13/2022 (Addendum) - Covid-19 spring booster vaccination programme
- HSS(MD) 13/2022 - Covid-19 spring booster vaccination programme
- HSS(MD) 12/2022 - antivirals or neutralising monoclonal antibodies (NMABS) for non-hospitalised patients with Covid-19 - update
- HSS(MD) 11/2022 - Covid-19 therapeutic alert: antivirals and neutralising monoclonal antibodies (NMABS) in the treatment of Covid 19 in hospitalised patients
- HSS(MD) 10/2022 - Remdesivir for patients hospitalised due to covid-19 (adults and adolescents 12 years and older) – update
- HSS(MD)9/2022 - JCVI update on advice for primary covid-19 vaccination of children aged 5 to 11 years
- HSS(MD) 08/2022 - Changes to the Vaccine of the Human Papilloma Virus (HPV) Vaccination Programme
- HSS(MD) 7/2022 - Updated departmental guidance on death certification
- HSS(MD) 06/2022 - Antivirals or neutralising monoclonal antibodies (NMABS) for non-hospitalised patients with covid-19 - update
- HSS(MD) 5/2022 - Covid-19 therapeutic alert: interleukin-6 inhibitors (tocilizumab or sarilumab) for adult patients hospitalised due to covid-19
- HSS(MD) 4/2022 - Covid-19 therapeutic alert: antivirals and neutralising monoclonal antibodies in the treatment of covid-19 in hospitalised patients - effective from 10 February 2022
- HSS(MD) 3/2022 - Palivizumab passive immunisation against respiratory syncytial virus (RSV) in at-risk pre-term infants
- HSS(MD) 02/2022 - Management of health and social care staff who are confirmed cases of Covid-19 - Updated Guidance - Revised
- HSS(MD) 02/2022 - Management of health and social care staff who are confirmed cases of Covid-19 - Updated Guidance
- HSS(MD) 01/2022 - Management of health and social care staff who are confirmed cases of Covid-19 or who close contacts of a confirmed case – update on guidance contained in HSS 91/2021